Skip to content

The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men

The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01317524
Enrollment
18
Registered
2011-03-17
Start date
2011-02-28
Completion date
2011-06-30
Last updated
2011-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Hyperlipidemias, Inflammation

Keywords

Milk, Homogenization, Postprandial hyperlipidemia, Postprandial inflammation, Overweight

Brief summary

The purpose of this study is to compare the effects of homogenized, unhomogenized and skimmed milk on postprandial metabolism in healthy overweight men

Interventions

DIETARY_SUPPLEMENTHomogenized milk

900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread

DIETARY_SUPPLEMENTUnhomogenized milk

900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread

DIETARY_SUPPLEMENTSkimmed Milk

900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread

Sponsors

Dutch Dairy Association (NZO)
CollaboratorUNKNOWN
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* men * aged between 18 and 70 years * Quetelet index between 25 - 30 kg/m2 * mean serum triacylglycerol (≤1.7 mmol/L (31))

Exclusion criteria

* women * indication for treatment with cholesterol-lowering drugs according to the Dutch Cholesterol Consensus (32) * lactose intolerance * current smoker * familial hypercholesterolemia * abuse of drugs * more than 21 alcoholic consumptions per week * no stable body weight (weight gain or loss \< 3 kg in the past three months) * use of medication or a diet known to affect serum lipid or glucose metabolism * severe medical conditions that might interfere with the study, such as epilepsy, asthma, chronic obstructive pulmonary disease, inflammatory bowel diseases and rheumatoid arthritis. * active cardiovascular disease like congestive heart failure or recent (\<6 months) event (acute myocardial infarction, cerebro vascular accident) * use of an investigational product within the previous 1 month * not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study * not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study * difficult venipuncture as evidenced during the screening visits

Design outcomes

Primary

MeasureTime frame
Incremental Area Under the triacylglycerol Curveduring 8 hours after meal consumption

Secondary

MeasureTime frame
Plasma inflammatory markersduring 8 hours after meal consumption
Markers of endothelial activationduring 8 hours after meal consumption

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026